MarketCap
Facebook
X
Telegram
Pluristem Therapeutics Income Statement 2025-2009 | PSTI
Brief overview of revenue and earnings at Pluristem Therapeutics
This overview is based on financial performance over the past five years. Revenue reported by Pluristem Therapeutics was $23 thousand at the beginning of the period and $1.3 million at the end. The total change was +5708.7%, with a CAGR of approximately 125.3%. Sales grew at a rate typical of a strong expansion phase.
Gross profit changed from $23 thousand to $654 thousand (+2743.5%). Gross margin moved from 100% to 49%. The margin decline reflects a less favorable sales-and-cost structure.
EBITDA was −$27.9 million at the beginning and −$21.9 million at the end of the period (+21.7%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was −121330.4% at the start and −1636.2% at the end. The business generated more EBITDA from each unit of revenue.
The final result was −$29.2 million initially and $23.2 million in the final year. A negative result turned positive over the five years.
Market capitalization changed from $167 million to $6.5 million (−96.1%). Capitalization lags the underlying business improvement.
Financial takeaway
The results contain several connected negative signals. Key strengths include higher operating efficiency, revenue expansion and a stronger final result. The weaker side of the profile includes a narrow EBITDA buffer, weaker gross profitability and lower investor confidence. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Pluristem Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.53 M | 5.4 M | 4.72 M | 33.2 M | 28.1 M | 167 M | 69.1 M | 130 M | 103 M | 118 M | 167 M | 181 M | 168 M | 147 M | 107 M | - | - |
Shares |
6.34 M | 5.24 M | 4.58 M | 32.2 M | 28.1 M | 18.2 M | 12.3 M | 10.6 M | 8.74 M | 7.95 M | 7.03 M | 6.35 M | 5.55 M | 4.4 M | 3.12 M | 20.9 M | 13.7 M |
Historical Prices |
1.03 | 1.03 | 1.03 | 1.03 | 1.78 | 6.34 | 3.75 | 9.6 | 14.3 | 11.4 | 13 | 30.4 | 41.1 | 33.2 | 22.5 | ||
Net Income |
23.2 M | 21.3 M | 28.9 M | -41.2 M | -49.9 M | -29.2 M | -35.3 M | -26.1 M | -27.8 M | -23.2 M | -24.7 M | -26.9 M | -21.2 M | -14.8 M | -10.8 M | -2.82 M | - |
Revenue |
1.34 M | 326 K | 287 K | 234 K | - | 23 K | 54 K | 50 K | - | 2.85 M | 379 K | 379 K | 679 K | 716 K | - | - | - |
Cost of Revenue |
682 K | 4 K | 9 K | - | - | - | 2 K | 2 K | - | 100 K | 13 K | 11 K | 20 K | 21 K | - | - | - |
Gross Profit |
654 K | 322 K | 278 K | 234 K | - | 23 K | 52 K | 48 K | - | 2.75 M | 366 K | 368 K | 659 K | 716 K | - | - | - |
Operating Income |
-22.2 M | -22.2 M | -27.2 M | -41.6 M | -50.6 M | -29.5 M | -35.5 M | -33.7 M | -28 M | -23.3 M | -25.3 M | -27.8 M | -22.2 M | -15 M | -11.1 M | -2.82 M | - |
Interest Expense |
-206 K | 1.68 M | 843 K | 887 K | 78 K | - | -2 K | -25 K | - | 23 K | - | - | - | - | - | - | - |
EBITDA |
-21.9 M | -21.9 M | -26.9 M | -40.5 M | -49.3 M | -27.9 M | -33.6 M | -31.7 M | -25.8 M | -21.2 M | -23.2 M | -25.9 M | -21.2 M | -14.6 M | -10.8 M | -2.62 M | - |
Operating Expenses |
- | - | - | - | - | 29.5 M | 35.6 M | 33.8 M | 28 M | 26.1 M | 25.6 M | 28.2 M | 22.9 M | 15.7 M | 11.1 M | 2.82 M | - |
General and Administrative Expenses |
9.98 M | 10 M | 11.8 M | 2.13 M | 5.16 M | 7.92 M | 9.16 M | 11.2 M | 6.93 M | 6.49 M | 6.46 M | 8.68 M | 5.65 M | - | - | 3.14 M | - |
All numbers in USD currency
Quarterly Income Statement Pluristem Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10.1 M | 9.26 M | 9 M | 9.26 M | 9 M | 7.89 M | 6.56 M | 5.55 M | 5.46 M | 5.41 M | 5.22 M | 5.19 M | 5.17 M | 41.2 M | 39.9 M | 33.2 M | 32.6 M | 32.5 M | 32.3 M | 32.1 M | 32 M | 32.1 M | 29.6 M | 25.7 M | 25.5 M | 25.7 M | 25.5 M | 15.9 M | 15.4 M | 15.9 M | 15.4 M | 11.6 M | 11.4 M | 11.4 M | 110 M | 105 M | 97.3 M | 105 M | 97.3 M | 81 M | 80.7 M | 81 M | 80.7 M | 79.4 M | 78.7 M | 79.4 M | 78.7 M | 70.1 M | 69.1 M | 70.1 M | 69.1 M | 61.5 M | 59.3 M | 61.5 M | 59.3 M | 57.5 M | 47.8 M | 57.5 M | 44.3 M | 43.7 M | 43 M | 42.4 M | 42.4 M |
Net Income |
-5.55 M | -6.54 M | -5.85 M | -6.54 M | -5.85 M | - | -6.15 M | -2.96 M | -5.88 M | - | -5.29 M | -4.9 M | -4.96 M | - | -7.62 M | -8.12 M | -6.12 M | -14.2 M | -9.86 M | -10.9 M | -11.4 M | -22.4 M | -14.3 M | -12.6 M | -8.49 M | -12.6 M | -8.49 M | -6.37 M | -7.14 M | -6.37 M | -7.14 M | -8.68 M | -8.79 M | - | -1.53 M | -8.23 M | -7.38 M | -8.23 M | -7.38 M | -6.61 M | -6.32 M | -6.61 M | -6.32 M | -3.96 M | -5.88 M | -3.96 M | -5.88 M | -6.24 M | -5.91 M | -6.24 M | -5.91 M | -6.7 M | -4.76 M | -6.7 M | -4.76 M | -4.49 M | -4 M | -4.49 K | -4 M | -1.99 K | -4.49 M | -1.99 M | -4.49 M |
Revenue |
167 K | 198 K | 316 K | 198 K | 316 K | - | 427 K | 185 K | 326 K | - | 71 K | 105 K | 54 K | - | 87 K | 2 K | 87 K | 89 K | 234 K | - | - | - | - | - | 23 K | - | - | 23 K | 54 K | 23 K | - | 50 K | 4 K | - | - | 50 K | - | 50 K | - | - | 2.85 M | - | - | 2.75 M | 95 K | 2.75 M | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 95 K | 195 K | 195 K | 195 | 195 K | 231 | 154 K | 231 K | 154 K |
Cost of Revenue |
111 K | 112 K | 201 K | 112 K | 201 K | - | 291 K | 74 K | 126 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | - | - | 1 K | 2 K | 1 K | - | 2 K | 2 K | - | - | 2 K | - | 2 K | - | - | 100 K | - | - | 97 K | 3 K | 97 K | 3 K | 4 K | 3 K | 4 K | 3 K | 3 K | 3 K | 3 K | 3 K | 6 K | 6 K | 6 | 6 K | 7 | 5 K | - | - |
Gross Profit |
56 K | 86 K | 115 K | 86 K | 115 K | - | 136 K | 111 K | 200 K | - | 71 K | 105 K | 54 K | - | - | - | - | - | - | - | - | - | - | - | 22 K | - | - | 22 K | 52 K | 22 K | - | 48 K | 4 K | - | - | 48 K | - | 48 K | - | - | 2.75 M | - | - | 2.66 M | 92 K | 2.66 M | 92 K | 91 K | 92 K | 91 K | 92 K | 92 K | 92 K | 92 K | 92 K | 189 K | 189 K | 189 | 189 K | 224 | 149 K | - | - |
Operating Income |
-6.54 M | -6.51 M | -6.35 M | -6.51 M | -6.35 M | - | -5.4 M | -4.96 M | -5.2 M | - | -5.53 M | -5.21 M | -5.38 M | - | -7.1 M | -6.68 M | -6.92 M | -13.6 M | -10.5 M | -10.8 M | -11.4 M | -22.2 M | -14.2 M | -13.1 M | -8.74 M | -13.1 M | -8.74 M | -6.37 M | -7.2 M | -6.37 M | -7.2 M | -8.33 M | -8.97 M | - | -9.05 M | -8.47 M | -7.44 M | -8.47 M | -7.44 M | -6.65 M | -6.56 M | -6.65 M | -6.56 M | -4.23 M | -5.52 M | -4.23 M | -5.52 M | -6.3 M | -5.62 M | -6.3 M | -5.62 M | -6.99 M | -4.86 M | -6.99 M | -4.86 M | -4.88 M | -4.19 M | -4.88 K | -4.19 M | -2.12 K | -4.33 M | -2.12 M | -4.33 M |
Interest Expense |
593 K | -143 K | 439 K | -143 K | 439 K | - | -723 K | 2.06 M | -621 K | - | 362 K | 435 K | 493 K | - | - | 212 K | 194 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.41 M | -6.38 M | -6.22 M | -6.38 M | -6.22 M | - | - | -4.89 M | -5.13 M | - | - | - | -5.31 M | - | - | -6.68 M | -6.82 M | -13.4 M | -10.5 M | -10.8 M | -11.1 M | -21.6 M | -14.2 M | -13.1 M | -8.39 M | -12.4 M | -8.39 M | -6.37 M | -6.73 M | -5.52 M | -6.73 M | -8.33 M | -8.47 M | - | -9.05 M | -8.47 M | -6.92 M | -7.44 M | -6.92 M | -6.65 M | -6 M | -5.54 M | -6 M | -4.23 M | -5.03 M | -3.2 M | -5.03 M | -6.3 M | -5.12 M | -5.3 M | -5.12 M | -6.99 M | -4.4 M | -6.05 M | -4.4 M | -4.88 M | -4.06 M | -4.61 K | -4.06 M | -2.12 K | -4.24 M | -1.92 M | -4.24 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.95 M | - | - | - | 4.38 M | 4.07 M | 4.84 M | 2.35 M | 4.49 M | 3.84 M | 2.7 M |
General and Administrative Expenses |
2.63 M | 2.77 M | 2.53 M | 2.77 M | 2.53 M | - | 2.49 M | 2.14 M | 2.51 M | - | 2.51 M | 2.35 M | 2.44 M | - | 310 | 2.9 M | 2.74 M | 5.64 M | 4.55 M | 4.29 M | 5.09 M | 9.38 M | 6.56 M | 5.1 M | 2.8 M | 5.1 M | 2.8 M | 1.75 M | 1.81 M | 1.75 M | 1.81 M | 2.12 M | 2.21 M | - | 2.67 M | 2.92 M | 2.76 M | 2.92 M | 2.76 M | 1.45 M | 1.56 M | 1.45 M | 1.56 M | 1.55 M | 1.49 M | 1.55 M | 1.49 M | 1.51 M | 1.68 M | 1.51 M | 1.68 M | 1.98 M | 1.83 M | 1.98 M | 1.83 M | 1.42 M | 1.68 M | 1.42 K | 1.68 M | 1.28 K | 1.64 M | 1.28 M | 1.64 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Pluristem Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
